Edwards Lifesciences Corporation (EW) Shares Sold by Foundry Partners LLC

Foundry Partners LLC reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 36.6% during the second quarter, Holdings Channel reports. The fund owned 3,020 shares of the medical research company’s stock after selling 1,745 shares during the period. Foundry Partners LLC’s holdings in Edwards Lifesciences Corporation were worth $357,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. YorkBridge Wealth Partners LLC purchased a new stake in Edwards Lifesciences Corporation during the first quarter worth about $110,000. NEXT Financial Group Inc increased its stake in Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after buying an additional 500 shares in the last quarter. Shine Investment Advisory Services Inc. purchased a new stake in Edwards Lifesciences Corporation during the second quarter worth about $126,000. Cornerstone Advisors Inc. increased its stake in Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after buying an additional 219 shares in the last quarter. Finally, Alexandria Capital LLC increased its stake in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares in the last quarter. Institutional investors own 84.67% of the company’s stock.

Shares of Edwards Lifesciences Corporation (NYSE EW) opened at 113.11 on Friday. The company has a market cap of $23.88 billion, a P/E ratio of 34.31 and a beta of 0.63. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. The firm has a 50-day moving average price of $116.42 and a 200-day moving average price of $106.02.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. The company had revenue of $842 million for the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.76 earnings per share. On average, equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

A number of research firms have issued reports on EW. Zacks Investment Research downgraded Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, May 18th. BidaskClub downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Bank of America Corporation boosted their price target on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. SunTrust Banks, Inc. boosted their price target on Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Royal Bank Of Canada boosted their price target on Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the company an “outperform” rating in a research note on Wednesday, April 26th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $121.13.

In other news, VP Patrick B. Verguet sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $114.88, for a total value of $1,148,800.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $115.99, for a total value of $3,816,071.00. The disclosure for this sale can be found here. Insiders have sold 149,281 shares of company stock worth $17,331,446 in the last quarter. 2.13% of the stock is currently owned by company insiders.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).